Prot #CTKI258AUS26: Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGF

Project: Research project

Project Details

Effective start/end date2/14/1412/31/14


  • United BioSource LLC (Prot #CTKI258AUS26)
  • Novartis Pharmaceuticals Corporation (Prot #CTKI258AUS26)